The need to streamline approval processes for clinical research in Canada.
作者信息
Lumia Celeste M, Gupta Samir, Sin Don D, Gershon Andrea S
机构信息
Research coordinator, Sunnybrook Health Sciences Centre, Toronto, Ont.
Respirologist and clinician scientist, Division of Respirology, Department of Medicine, St. Michael's Hospital; Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ont.
出版信息
CMAJ. 2023 Apr 11;195(14):E517. doi: 10.1503/cmaj.148341-l.
Abstract
摘要
相似文献
1
The need to streamline approval processes for clinical research in Canada.简化加拿大临床研究审批流程的必要性。
CMAJ. 2023 Apr 11;195(14):E517. doi: 10.1503/cmaj.148341-l.
2
The timeliness of new drug approvals in Canada.加拿大新药审批的及时性。
Int J Health Serv. 1995;25(1):153-65; discussion 167-71. doi: 10.2190/3XHM-EW8F-5HJY-2D5N.
3
A comparison of regulatory approval times for new chemical entities in Australia, Canada, Sweden, the United Kingdom, and the United States.澳大利亚、加拿大、瑞典、英国和美国新化学实体的监管批准时间比较。
J Clin Pharmacol. 1992 Oct;32(10):889-96. doi: 10.1002/j.1552-4604.1992.tb04634.x.
4
Canadian and US drug approval times and safety considerations.加拿大和美国的药品审批时间及安全考量。
Ann Pharmacother. 2003 Oct;37(10):1403-8. doi: 10.1345/aph.1D110.
5
Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made?1999年至2001年加拿大新药审评与批准的及时性：是否取得了进展？
Clin Ther. 2003 Apr;25(4):1230-47. doi: 10.1016/s0149-2918(03)80080-2.
6
Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration.中加和中美两国在肿瘤药物审批方面的比较。
Cancer. 2015 May 15;121(10):1688-93. doi: 10.1002/cncr.29246. Epub 2015 Jan 20.
7
Who needs faster drug approval times in Canada: the public or the industry?在加拿大，谁更需要更快的药物审批时间：公众还是制药行业？
Int J Health Serv. 1994;24(2):253-64. doi: 10.2190/NYKA-UH7E-WBQ4-RD1J.
8
Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.加拿大和新西兰针对罕见病的新药的监管批准及纳入公共药品计划清单。
J Popul Ther Clin Pharmacol. 2020 Jun 1;27(2):e58-e67. doi: 10.15586/jptcp.v27i2.673.
9
Prescription drug approval in Canada: a risk-benefit analysis.
J Can Dent Assoc. 1995 Jul;61(7):578-9.
引用本文的文献
1
Core elements of consent documentation for clinical research in Canada: guidance for policy.加拿大临床研究同意书文件的核心要素：政策指南
CMAJ. 2025 Sep 14;197(30):E941-E952. doi: 10.1503/cmaj.250500.
2
Addressing Challenges to Enhance Clinical Research in Portugal: Insights from the OncoT3 Expert Group Delphi Study.应对挑战以加强葡萄牙的临床研究：OncoT3专家小组德尔菲研究的见解
Cureus. 2024 Nov 15;16(11):e73720. doi: 10.7759/cureus.73720. eCollection 2024 Nov.
本文引用的文献
1
How Canada can better embed randomized trials into clinical care.加拿大如何能更好地将随机试验纳入临床护理。
CMAJ. 2020 Aug 10;192(32):E928-E929. doi: 10.1503/cmaj.201764. Epub 2020 Jul 30.
Zotero 插件